{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:10:44Z","timestamp":1792602644576,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40257-020-00527-x","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T17:03:50Z","timestamp":1592413430000},"page":"567-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"21","author":[{"given":"Lisa A.","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iftikhar","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A.","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Beazley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naimish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M. H.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Shumel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"527_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4:1.","journal-title":"Nat Rev Dis Primers."},{"key":"527_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13:425\u201337.","journal-title":"Expert Rev Clin Immunol."},{"key":"527_CR3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jaip.2017.08.005","volume":"5","author":"M Boguniewicz","year":"2017","unstructured":"Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5:1519\u201331.","journal-title":"J Allergy Clin Immunol Pract."},{"key":"527_CR4","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6\u00a0Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111:5147\u201352.","journal-title":"Proc Natl Acad Sci USA."},{"key":"527_CR5","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111:5153\u20138.","journal-title":"Proc Natl Acad Sci USA."},{"key":"527_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0091-6749(96)70246-4","volume":"98","author":"Q Hamid","year":"1996","unstructured":"Hamid Q, Naseer T, Minshall EM, et al. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol. 1996;98:225\u201331.","journal-title":"J Allergy Clin Immunol."},{"key":"527_CR7","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.4049\/jimmunol.171.6.3262","volume":"171","author":"I Nomura","year":"2003","unstructured":"Nomura I, Goleva E, Howell MD, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol. 2003;171:3262\u20139.","journal-title":"J Immunol."},{"key":"527_CR8","unstructured":"US Food and Drug Administration. DUPIXENT\u00ae (dupilumab). Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761055s014lbl.pdf. Accessed 27 Mar 2020."},{"key":"527_CR9","unstructured":"European Medicines Agency. DUPIXENT\u00ae (dupilumab). Summary of product characteristics. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2019\/20190801145601\/anx_145601_en.pdf. Accessed 27 Mar 2020."},{"key":"527_CR10","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287\u2013303.","journal-title":"Lancet"},{"key":"527_CR11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178:1083\u2013101.","journal-title":"Br J Dermatol"},{"key":"527_CR12","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335\u201348.","journal-title":"N Engl J Med"},{"key":"527_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2020","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82:377\u201388.","journal-title":"J Am Acad Dermatol"},{"key":"527_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130\u20139.","journal-title":"N Engl J Med"},{"key":"527_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jaad.2018.07.048","volume":"80","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt A, Simpson EL, Tyring SK, et al. Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2019;80:158\u201367.","journal-title":"J Am Acad Dermatol"},{"key":"527_CR16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjd.18476","volume":"182","author":"MJ Cork","year":"2020","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label and subsequent phase III open-label extension trial. Br J Dermatol. 2020;182:85\u201396.","journal-title":"Br J Dermatol"},{"key":"527_CR17","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/cpt.1058","volume":"104","author":"JD Davis","year":"2018","unstructured":"Davis JD, Bansal A, Hassman D, et al. Evaluation of potential disease-mediated drug\u2013drug interaction in patients with moderate-to-severe atopic dermatitis receiving dupilumab. Clin Pharmacol Ther. 2018;104:1146\u201354.","journal-title":"Clin Pharmacol Ther"},{"key":"527_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:155\u201372.","journal-title":"J Allergy Clin Immunol."},{"key":"527_CR19","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","volume":"134","author":"JD Hamilton","year":"2014","unstructured":"Hamilton JD, Su\u00e1rez-Fari\u00f1as M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293\u2013300.","journal-title":"J Allergy Clin Immunol."},{"key":"527_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","volume":"387","author":"D Tha\u00e7i","year":"2016","unstructured":"Tha\u00e7i D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387:40\u201352.","journal-title":"Lancet"},{"issue":"2","key":"527_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm M, Simpson EL, Tha\u00e7i D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(2):131\u201343.","journal-title":"JAMA Dermatol."},{"key":"527_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/bjd.16078","volume":"178","author":"PP Vakharia","year":"2018","unstructured":"Vakharia PP, Chopra R, Sacotte R, et al. Severity strata for five patient-reported outcomes in adults with atopic dermatitis. Br J Dermatol. 2018;178:925\u201330.","journal-title":"Br J Dermatol"},{"key":"527_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"181","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181:459\u201373.","journal-title":"Br J Dermatol"},{"key":"527_CR24","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2340\/00015555-2703","volume":"97","author":"S Ruff","year":"2017","unstructured":"Ruff S, Egeberg A, Andersen YMF, et al. Prevalence of Cancer in Adult Patients with Atopic Dermatitis: a nationwide study. Acta Derm Venereol. 2017;97:1127\u20139.","journal-title":"Acta Derm Venereol"},{"key":"527_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/ijd.13857","volume":"57","author":"JM Cho","year":"2018","unstructured":"Cho JM, Davis DMR, Wetter DA, et al. Association between atopic dermatitis and squamous cell carcinoma: a case\u2013control study. Int J Dermatol. 2018;57:313\u20136.","journal-title":"Int J Dermatol"},{"key":"527_CR26","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archderm.141.9.1123","volume":"141","author":"L Hagstr\u00f6mer","year":"2005","unstructured":"Hagstr\u00f6mer L, Ye W, Nyr\u00e9n O, Emtestam L. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol. 2005;141:1123\u20137.","journal-title":"Arch Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00527-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-020-00527-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00527-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T19:20:57Z","timestamp":1623871257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-020-00527-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["527"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00527-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"17 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Open access was funded by Sanofi and Regeneron Pharmaceuticals, Inc. This research was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. (ClinicalTrials.gov identifier: NCT01949311). The study sponsors participated in the study design; collection, analysis, and interpretation of the data; writing of the report; and the decision to submit the article for publication. Medical writing and editorial assistance was provided by Carolyn Ellenberger, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lisa A. Beck: AbbVie, LEO Pharma, Pfizer, Regeneron Pharmaceuticals, Inc.\u2014investigator and consultant; Allakos, Arena Pharma, Astra Zeneca, LEO Pharma, Eli Lilly, Novan, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, UCB, Vimalan\u2014consultant; Medtronics, Pfizer\u2014stock owner. Diamant Tha\u00e7i: AbbVie, Almirall, Amgen, Asana Biosciences, Beiersdorf, Boehringer Ingelheim, Celgene, Dermira, DS Biopharma, Eli Lilly, Galapagos, Galderma, GlaxoSmithKline, Janssen-Cilag, LEO Pharma, Merck Sharp & Dohme, MorphoSys, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sandoz, Sanofi, Sun Pharma, UCB\u2014consultant, advisory board member, and\/or investigator. Mette Deleuran: AbbVie, Almirall, Eli Lilly, Galapagos, LEO Pharma, Meda Pharma, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme\u2014received research support and\/or honoraria for lecturing, and consulting\/advisory board agreements. Andrew Blauvelt: AbbVie, Aclaris, Almirall, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira, Eli Lilly, FLX Bio, Forte, Galderma, Janssen, LEO Pharma, Novartis, Ortho Derm, Pfizer, Regeneron Pharmaceuticals, Inc., Sandoz, Sanofi Genzyme, Sun Pharma, UCB\u2014scientific adviser and clinical study investigator; AbbVie\u2014paid speaker. Robert Bissonnette: AbbVie, Aquinox Pharmaceuticals, Arcutis Antiobix, Asana Biosciences, Astellas, Boehringer Ingelheim, Brickell Biotech, Dermavant, Dermira, Dignity Sciences, Eli Lilly, Galderma, Glenmark, GlaxoSmithKline-Stiefel, Hoffman-La Roche, Kiniksa, Incyte, LEO Pharma, NeoKera, Pfizer, Ralexar Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Vitae\u2014consultant and\/or has received grants\/research support; Innovaderm Research\u2014shareholder. Marjolein de Bruin-Weller: Regeneron Pharmaceuticals, Inc., Sanofi Genzyme\u2014Principal Investigator, advisory board member, consultant; AbbVie\u2014Principal Investigator, advisory board member; Pfizer, Eli Lilly, UCB\u2014advisory board member. Michihiro Hide: Kaken Pharmaceutical, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Maruho, MDS, Mitsubishi Tanabe Pharma, Sanofi KK, Taiho Pharma, Teikoku Seiyaku, Torii Pharmaceutical, Uriach\u2014honoraria for lectures. Lawrence Sher: Aimmune, Optinose, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme\u2014advisory board member; Regeneron Pharmaceuticals, Inc., Sanofi Genzyme\u2014speaker fees; Aimmune, Amgen, Astra Zeneca, Circassia, DBV, Galderma, GlaxoSmithKline, Lupin, Merck, Mylan, Novartis, Novo Nordisk, Optinose, Pearl, Pfizer, Pulmagen, Roxane, Sanofi, Spirometrix, Teva, Vectura, Watson\u2014clinical trials funding. Iftikhar Hussain: CSL Behring, Genentech, Optinose, Pfizer\u2014advisory board member; AbbVie, AnaptysBio, Asana Biosciences, Astra Zeneca, CSL Behring, Genentech, GlaxoSmithKline, Gossamer Bio, HAL Allergy, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Merck, Novartis, Optinose, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Shire, Vanda\u2014Principal Investigator. Zhen Chen, Faisal A. Khokhar, Bethany Beazley, Marcella Ruddy, Neil M.H. Graham, Marius Ardeleanu, Brad Shumel: Regeneron Pharmaceuticals, Inc.\u2014employees and shareholders. Naimish Patel: Sanofi\u2014employee, may hold stock and\/or stock options in the company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the ethical standards of the responsible committees and the Declaration of Helsinki, and with the International Conference on Harmonisation guidelines for Good Clinical Practice. The trial was overseen by an independent data and safety monitoring board. The protocol was reviewed and approved by Institutional Review Boards\/Ethics Committees at all centers.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients or their proxies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}